STOCK TITAN

[Form 4] Elanco Animal Health Incorporated Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.

Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern’s employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.

Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company’s legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law §242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from “EYEN” to “HYPD” beginning July 3, 2025.

Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed “filed” for Exchange Act liability.

Exhibits:

  • 3.1 – Certificate of Amendment (Name Change)
  • 10.1 – Separation and Release Agreement (COO)
  • 99.1 – Press Release announcing changes
  • 104 – Inline XBRL cover page

The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.

Punti salienti del Modulo 8-K: Hyperion DeFi, Inc. (precedentemente Eyenovia, Inc.) ha presentato un rapporto corrente che riguarda due questioni principali: (1) l’uscita del suo Chief Operating Officer e (2) il cambio del nome societario e del ticker.

Uscita dell’esecutivo (Punto 5.02): A partire dal 1° luglio 2025, il rapporto di lavoro del COO Bren Kern è terminato in seguito a una riduzione del personale precedentemente annunciata. In base a un Accordo di Separazione e Liberatoria, riceverà 12 mesi di stipendio base e fino a 12 mesi di copertura sanitaria continuativa, subordinati a standard clausole di liberatoria e di non concorrenza. L’accordo è allegato come Esibizione 10.1.

Cambio di nome e ticker (Punto 5.03): Un Certificato di Modifica depositato il 30 giugno 2025 ha cambiato il nome legale della società da Eyenovia, Inc. a Hyperion DeFi, Inc., con effetto dalle 8:00 a.m. ET del 1° luglio 2025. L’approvazione del consiglio di amministrazione ai sensi della Delaware General Corporation Law §242 è stata sufficiente; non è stato necessario il voto degli azionisti. Le azioni ordinarie mantengono gli stessi diritti e CUSIP, ma il ticker Nasdaq passerà da “EYEN” a “HYPD” a partire dal 3 luglio 2025.

Divulgazione Reg FD (Punto 7.01): È stato fornito un comunicato stampa riguardante il rebranding e il cambio di ticker (Esibizione 99.1), che non è considerato “depositato” ai fini della responsabilità ai sensi dell’Exchange Act.

Esibizioni:

  • 3.1 – Certificato di Modifica (Cambio Nome)
  • 10.1 – Accordo di Separazione e Liberatoria (COO)
  • 99.1 – Comunicato stampa che annuncia i cambiamenti
  • 104 – Pagina di copertina Inline XBRL

La presentazione è principalmente di natura amministrativa; segnala un rebranding strategico senza modificare la struttura azionaria, mentre contemporaneamente rende nota la rotazione nel management senior che potrebbe sollevare preoccupazioni sulla continuità.

Aspectos destacados del Formulario 8-K: Hyperion DeFi, Inc. (anteriormente Eyenovia, Inc.) presentó un informe actual que cubre dos asuntos principales: (1) la salida de su Director de Operaciones y (2) un cambio de nombre corporativo y ticker.

Salida ejecutiva (Ítem 5.02): A partir del 1 de julio de 2025, el empleo del COO Bren Kern terminó en relación con una reducción de personal anunciada previamente. Bajo un Acuerdo de Separación y Liberación, recibirá 12 meses de salario base y hasta 12 meses de beneficios continuos de salud, condicionado a las disposiciones estándar de liberación y convenios. El acuerdo está adjunto como Anexo 10.1.

Cambio de nombre y ticker (Ítem 5.03): Un Certificado de Enmienda presentado el 30 de junio de 2025 cambió el nombre legal de la compañía de Eyenovia, Inc. a Hyperion DeFi, Inc., con efecto a las 8:00 a.m. ET del 1 de julio de 2025. La aprobación del consejo bajo la Ley General de Corporaciones de Delaware §242 fue suficiente; no se requirió voto de los accionistas. Las acciones comunes mantienen los mismos derechos y CUSIP, pero el ticker de Nasdaq cambiará de “EYEN” a “HYPD” a partir del 3 de julio de 2025.

Divulgación Reg FD (Ítem 7.01): Se proporcionó un comunicado de prensa sobre el cambio de marca y ticker (Anexo 99.1) y no se considera “presentado” para responsabilidad bajo la Ley de Intercambio.

Anexos:

  • 3.1 – Certificado de Enmienda (Cambio de Nombre)
  • 10.1 – Acuerdo de Separación y Liberación (COO)
  • 99.1 – Comunicado de prensa anunciando los cambios
  • 104 – Página de portada Inline XBRL

La presentación es principalmente administrativa; señala un cambio estratégico de marca sin alterar la estructura accionaria, mientras que simultáneamente divulga la rotación en la alta dirección que podría generar preocupaciones sobre la continuidad.

Form 8-K 주요 내용: Hyperion DeFi, Inc. (이전 명칭: Eyenovia, Inc.)는 두 가지 주요 사항에 대한 현재 보고서를 제출했습니다: (1) 최고운영책임자(COO)의 퇴임과 (2) 회사명 및 주식 티커 변경.

임원 퇴임 (항목 5.02): 2025년 7월 1일부로 COO 브렌 케른(Bren Kern)의 고용이 이전에 발표된 인력 감축과 관련하여 종료되었습니다. 분리 및 면책 합의서에 따라 그는 기본 급여 12개월분과 최대 12개월간 건강보험 혜택을 계속 받게 되며, 이는 표준 면책 및 계약 조항에 조건부입니다. 해당 합의서는 부속서 10.1로 첨부되어 있습니다.

회사명 및 티커 변경 (항목 5.03): 2025년 6월 30일 제출된 정관 수정 증명서에 따라 회사의 법적 명칭이 Eyenovia, Inc.에서 Hyperion DeFi, Inc.로 변경되었으며, 2025년 7월 1일 오전 8시(동부시간)부터 효력이 발생합니다. 델라웨어 일반법 §242에 따른 이사회 승인만으로 충분하며 주주 투표는 필요하지 않았습니다. 보통주는 동일한 권리와 CUSIP을 유지하지만, 나스닥 티커는 2025년 7월 3일부터 “EYEN”에서 “HYPD”로 변경됩니다.

Reg FD 공시 (항목 7.01): 리브랜딩 및 티커 변경에 관한 보도자료가 제공되었으며(부속서 99.1), 이는 증권거래법상 ‘제출된’ 문서로 간주되지 않습니다.

첨부 문서:

  • 3.1 – 정관 수정 증명서 (회사명 변경)
  • 10.1 – 분리 및 면책 합의서 (COO)
  • 99.1 – 변경 사항 발표 보도자료
  • 104 – Inline XBRL 표지 페이지

이번 제출은 주로 행정적 성격이며, 주식 구조를 변경하지 않는 전략적 리브랜딩을 알리는 동시에 경영진 교체 사실을 공개하여 연속성에 대한 우려를 제기할 수 있습니다.

Points clés du Formulaire 8-K : Hyperion DeFi, Inc. (anciennement Eyenovia, Inc.) a déposé un rapport actuel couvrant deux sujets principaux : (1) le départ de son directeur des opérations et (2) un changement de nom de la société et du ticker.

Départ de l’exécutif (Point 5.02) : À compter du 1er juillet 2025, l’emploi du COO Bren Kern a pris fin dans le cadre d’une réduction de personnel annoncée précédemment. Selon un accord de séparation et de libération, il recevra 12 mois de salaire de base et jusqu’à 12 mois de prestations de santé continues, sous réserve des clauses habituelles de libération et de non-concurrence. L’accord est joint en tant que pièce 10.1.

Changement de nom et de ticker (Point 5.03) : Un certificat de modification déposé le 30 juin 2025 a changé le nom légal de la société de Eyenovia, Inc. à Hyperion DeFi, Inc., effectif à 8h00 ET le 1er juillet 2025. L’approbation du conseil d’administration conformément à la Delaware General Corporation Law §242 a suffi ; aucun vote des actionnaires n’était requis. Les actions ordinaires conservent les mêmes droits et CUSIP, mais le ticker Nasdaq passera de « EYEN » à « HYPD » à partir du 3 juillet 2025.

Divulgation Reg FD (Point 7.01) : Un communiqué de presse concernant le rebranding et le changement de ticker a été fourni (pièce 99.1) et n’est pas considéré comme « déposé » au titre de la responsabilité de la Exchange Act.

Pièces jointes :

  • 3.1 – Certificat de modification (changement de nom)
  • 10.1 – Accord de séparation et de libération (COO)
  • 99.1 – Communiqué de presse annonçant les changements
  • 104 – Page de couverture Inline XBRL

Le dépôt est principalement administratif ; il signale un rebranding stratégique sans modifier la structure des actions, tout en divulguant simultanément un changement de la haute direction qui pourrait soulever des inquiétudes quant à la continuité.

Form 8-K Highlights: Hyperion DeFi, Inc. (ehemals Eyenovia, Inc.) reichte einen aktuellen Bericht ein, der zwei Hauptpunkte behandelt: (1) den Weggang des Chief Operating Officer und (2) eine Änderung des Firmennamens und des Tickers.

Abgang des Geschäftsführers (Punkt 5.02): Zum 1. Juli 2025 endete die Anstellung von COO Bren Kern im Zusammenhang mit einer zuvor angekündigten Personalreduzierung. Im Rahmen einer Trennungs- und Freigabevereinbarung erhält er 12 Monate Grundgehalt und bis zu 12 Monate fortgesetzte Krankenversicherungsleistungen, vorbehaltlich der üblichen Freigabe- und Wettbewerbsverbotsklauseln. Die Vereinbarung ist als Anhang 10.1 beigefügt.

Name- und Tickeränderung (Punkt 5.03): Eine am 30. Juni 2025 eingereichte Änderungsurkunde änderte den rechtlichen Namen der Gesellschaft von Eyenovia, Inc. zu Hyperion DeFi, Inc., wirksam ab 8:00 Uhr ET am 1. Juli 2025. Die Zustimmung des Vorstands gemäß Delaware General Corporation Law §242 war ausreichend; eine Aktionärsabstimmung war nicht erforderlich. Die Stammaktien behalten dieselben Rechte und CUSIP, aber das Nasdaq-Tickersymbol wird ab dem 3. Juli 2025 von „EYEN“ auf „HYPD“ geändert.

Reg FD Offenlegung (Punkt 7.01): Eine Pressemitteilung bezüglich des Rebrandings und der Tickeränderung wurde bereitgestellt (Anhang 99.1) und gilt nicht als „eingereicht“ im Sinne der Exchange Act Haftung.

Anlagen:

  • 3.1 – Änderungsurkunde (Namensänderung)
  • 10.1 – Trennungs- und Freigabevereinbarung (COO)
  • 99.1 – Pressemitteilung zur Ankündigung der Änderungen
  • 104 – Inline XBRL Titelseite

Die Einreichung ist hauptsächlich administrativer Natur; sie signalisiert ein strategisches Rebranding ohne Änderung der Aktienstruktur, während gleichzeitig ein Wechsel im oberen Management offengelegt wird, der Bedenken hinsichtlich der Kontinuität hervorrufen könnte.

Positive
  • No effect on shareholder rights or CUSIP; the name and ticker change occur without altering voting power or transferability of existing common shares.
Negative
  • Departure of Chief Operating Officer amid a reduction-in-force may increase operational risk and reflects ongoing restructuring efforts.

Insights

TL;DR Neutral filing: administrative rebrand, ticker change, and COO exit; no financial metrics or guidance adjustments disclosed.

The 8-K lacks hard financial data and does not amend prior guidance. The name and ticker change are structurally neutral—no impact on voting rights, share count, or CUSIP. Markets often view rebranding as cosmetic unless paired with a new strategy, which is not provided here. The severance package for the COO is modest (one-year salary and benefits) and already contemplated in his 2022 employment agreement, suggesting no extraordinary cash outflow. However, executive turnover amid a reduction-in-force can elevate operational risk and signal cost-control measures. Overall, the disclosure does not materially change valuation drivers.

TL;DR Governance impact minor; board-approved name change, no shareholder vote, COO departure underscores workforce restructuring.

Using Delaware GCL §242, the board unilaterally executed the name change—standard practice with minimal governance implications. Shareholders retain identical rights, and ticker migration is straightforward for brokers. The COO’s separation, tied to a company-wide RIF, could concentrate decision-making power and may warrant scrutiny of succession planning. The release of claims and covenant compliance are customary, limiting litigation exposure. No other bylaw or charter amendments were introduced. From a governance lens, the filing is routine but worth monitoring for further leadership changes.

Punti salienti del Modulo 8-K: Hyperion DeFi, Inc. (precedentemente Eyenovia, Inc.) ha presentato un rapporto corrente che riguarda due questioni principali: (1) l’uscita del suo Chief Operating Officer e (2) il cambio del nome societario e del ticker.

Uscita dell’esecutivo (Punto 5.02): A partire dal 1° luglio 2025, il rapporto di lavoro del COO Bren Kern è terminato in seguito a una riduzione del personale precedentemente annunciata. In base a un Accordo di Separazione e Liberatoria, riceverà 12 mesi di stipendio base e fino a 12 mesi di copertura sanitaria continuativa, subordinati a standard clausole di liberatoria e di non concorrenza. L’accordo è allegato come Esibizione 10.1.

Cambio di nome e ticker (Punto 5.03): Un Certificato di Modifica depositato il 30 giugno 2025 ha cambiato il nome legale della società da Eyenovia, Inc. a Hyperion DeFi, Inc., con effetto dalle 8:00 a.m. ET del 1° luglio 2025. L’approvazione del consiglio di amministrazione ai sensi della Delaware General Corporation Law §242 è stata sufficiente; non è stato necessario il voto degli azionisti. Le azioni ordinarie mantengono gli stessi diritti e CUSIP, ma il ticker Nasdaq passerà da “EYEN” a “HYPD” a partire dal 3 luglio 2025.

Divulgazione Reg FD (Punto 7.01): È stato fornito un comunicato stampa riguardante il rebranding e il cambio di ticker (Esibizione 99.1), che non è considerato “depositato” ai fini della responsabilità ai sensi dell’Exchange Act.

Esibizioni:

  • 3.1 – Certificato di Modifica (Cambio Nome)
  • 10.1 – Accordo di Separazione e Liberatoria (COO)
  • 99.1 – Comunicato stampa che annuncia i cambiamenti
  • 104 – Pagina di copertina Inline XBRL

La presentazione è principalmente di natura amministrativa; segnala un rebranding strategico senza modificare la struttura azionaria, mentre contemporaneamente rende nota la rotazione nel management senior che potrebbe sollevare preoccupazioni sulla continuità.

Aspectos destacados del Formulario 8-K: Hyperion DeFi, Inc. (anteriormente Eyenovia, Inc.) presentó un informe actual que cubre dos asuntos principales: (1) la salida de su Director de Operaciones y (2) un cambio de nombre corporativo y ticker.

Salida ejecutiva (Ítem 5.02): A partir del 1 de julio de 2025, el empleo del COO Bren Kern terminó en relación con una reducción de personal anunciada previamente. Bajo un Acuerdo de Separación y Liberación, recibirá 12 meses de salario base y hasta 12 meses de beneficios continuos de salud, condicionado a las disposiciones estándar de liberación y convenios. El acuerdo está adjunto como Anexo 10.1.

Cambio de nombre y ticker (Ítem 5.03): Un Certificado de Enmienda presentado el 30 de junio de 2025 cambió el nombre legal de la compañía de Eyenovia, Inc. a Hyperion DeFi, Inc., con efecto a las 8:00 a.m. ET del 1 de julio de 2025. La aprobación del consejo bajo la Ley General de Corporaciones de Delaware §242 fue suficiente; no se requirió voto de los accionistas. Las acciones comunes mantienen los mismos derechos y CUSIP, pero el ticker de Nasdaq cambiará de “EYEN” a “HYPD” a partir del 3 de julio de 2025.

Divulgación Reg FD (Ítem 7.01): Se proporcionó un comunicado de prensa sobre el cambio de marca y ticker (Anexo 99.1) y no se considera “presentado” para responsabilidad bajo la Ley de Intercambio.

Anexos:

  • 3.1 – Certificado de Enmienda (Cambio de Nombre)
  • 10.1 – Acuerdo de Separación y Liberación (COO)
  • 99.1 – Comunicado de prensa anunciando los cambios
  • 104 – Página de portada Inline XBRL

La presentación es principalmente administrativa; señala un cambio estratégico de marca sin alterar la estructura accionaria, mientras que simultáneamente divulga la rotación en la alta dirección que podría generar preocupaciones sobre la continuidad.

Form 8-K 주요 내용: Hyperion DeFi, Inc. (이전 명칭: Eyenovia, Inc.)는 두 가지 주요 사항에 대한 현재 보고서를 제출했습니다: (1) 최고운영책임자(COO)의 퇴임과 (2) 회사명 및 주식 티커 변경.

임원 퇴임 (항목 5.02): 2025년 7월 1일부로 COO 브렌 케른(Bren Kern)의 고용이 이전에 발표된 인력 감축과 관련하여 종료되었습니다. 분리 및 면책 합의서에 따라 그는 기본 급여 12개월분과 최대 12개월간 건강보험 혜택을 계속 받게 되며, 이는 표준 면책 및 계약 조항에 조건부입니다. 해당 합의서는 부속서 10.1로 첨부되어 있습니다.

회사명 및 티커 변경 (항목 5.03): 2025년 6월 30일 제출된 정관 수정 증명서에 따라 회사의 법적 명칭이 Eyenovia, Inc.에서 Hyperion DeFi, Inc.로 변경되었으며, 2025년 7월 1일 오전 8시(동부시간)부터 효력이 발생합니다. 델라웨어 일반법 §242에 따른 이사회 승인만으로 충분하며 주주 투표는 필요하지 않았습니다. 보통주는 동일한 권리와 CUSIP을 유지하지만, 나스닥 티커는 2025년 7월 3일부터 “EYEN”에서 “HYPD”로 변경됩니다.

Reg FD 공시 (항목 7.01): 리브랜딩 및 티커 변경에 관한 보도자료가 제공되었으며(부속서 99.1), 이는 증권거래법상 ‘제출된’ 문서로 간주되지 않습니다.

첨부 문서:

  • 3.1 – 정관 수정 증명서 (회사명 변경)
  • 10.1 – 분리 및 면책 합의서 (COO)
  • 99.1 – 변경 사항 발표 보도자료
  • 104 – Inline XBRL 표지 페이지

이번 제출은 주로 행정적 성격이며, 주식 구조를 변경하지 않는 전략적 리브랜딩을 알리는 동시에 경영진 교체 사실을 공개하여 연속성에 대한 우려를 제기할 수 있습니다.

Points clés du Formulaire 8-K : Hyperion DeFi, Inc. (anciennement Eyenovia, Inc.) a déposé un rapport actuel couvrant deux sujets principaux : (1) le départ de son directeur des opérations et (2) un changement de nom de la société et du ticker.

Départ de l’exécutif (Point 5.02) : À compter du 1er juillet 2025, l’emploi du COO Bren Kern a pris fin dans le cadre d’une réduction de personnel annoncée précédemment. Selon un accord de séparation et de libération, il recevra 12 mois de salaire de base et jusqu’à 12 mois de prestations de santé continues, sous réserve des clauses habituelles de libération et de non-concurrence. L’accord est joint en tant que pièce 10.1.

Changement de nom et de ticker (Point 5.03) : Un certificat de modification déposé le 30 juin 2025 a changé le nom légal de la société de Eyenovia, Inc. à Hyperion DeFi, Inc., effectif à 8h00 ET le 1er juillet 2025. L’approbation du conseil d’administration conformément à la Delaware General Corporation Law §242 a suffi ; aucun vote des actionnaires n’était requis. Les actions ordinaires conservent les mêmes droits et CUSIP, mais le ticker Nasdaq passera de « EYEN » à « HYPD » à partir du 3 juillet 2025.

Divulgation Reg FD (Point 7.01) : Un communiqué de presse concernant le rebranding et le changement de ticker a été fourni (pièce 99.1) et n’est pas considéré comme « déposé » au titre de la responsabilité de la Exchange Act.

Pièces jointes :

  • 3.1 – Certificat de modification (changement de nom)
  • 10.1 – Accord de séparation et de libération (COO)
  • 99.1 – Communiqué de presse annonçant les changements
  • 104 – Page de couverture Inline XBRL

Le dépôt est principalement administratif ; il signale un rebranding stratégique sans modifier la structure des actions, tout en divulguant simultanément un changement de la haute direction qui pourrait soulever des inquiétudes quant à la continuité.

Form 8-K Highlights: Hyperion DeFi, Inc. (ehemals Eyenovia, Inc.) reichte einen aktuellen Bericht ein, der zwei Hauptpunkte behandelt: (1) den Weggang des Chief Operating Officer und (2) eine Änderung des Firmennamens und des Tickers.

Abgang des Geschäftsführers (Punkt 5.02): Zum 1. Juli 2025 endete die Anstellung von COO Bren Kern im Zusammenhang mit einer zuvor angekündigten Personalreduzierung. Im Rahmen einer Trennungs- und Freigabevereinbarung erhält er 12 Monate Grundgehalt und bis zu 12 Monate fortgesetzte Krankenversicherungsleistungen, vorbehaltlich der üblichen Freigabe- und Wettbewerbsverbotsklauseln. Die Vereinbarung ist als Anhang 10.1 beigefügt.

Name- und Tickeränderung (Punkt 5.03): Eine am 30. Juni 2025 eingereichte Änderungsurkunde änderte den rechtlichen Namen der Gesellschaft von Eyenovia, Inc. zu Hyperion DeFi, Inc., wirksam ab 8:00 Uhr ET am 1. Juli 2025. Die Zustimmung des Vorstands gemäß Delaware General Corporation Law §242 war ausreichend; eine Aktionärsabstimmung war nicht erforderlich. Die Stammaktien behalten dieselben Rechte und CUSIP, aber das Nasdaq-Tickersymbol wird ab dem 3. Juli 2025 von „EYEN“ auf „HYPD“ geändert.

Reg FD Offenlegung (Punkt 7.01): Eine Pressemitteilung bezüglich des Rebrandings und der Tickeränderung wurde bereitgestellt (Anhang 99.1) und gilt nicht als „eingereicht“ im Sinne der Exchange Act Haftung.

Anlagen:

  • 3.1 – Änderungsurkunde (Namensänderung)
  • 10.1 – Trennungs- und Freigabevereinbarung (COO)
  • 99.1 – Pressemitteilung zur Ankündigung der Änderungen
  • 104 – Inline XBRL Titelseite

Die Einreichung ist hauptsächlich administrativer Natur; sie signalisiert ein strategisches Rebranding ohne Änderung der Aktienstruktur, während gleichzeitig ein Wechsel im oberen Management offengelegt wird, der Bedenken hinsichtlich der Kontinuität hervorrufen könnte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Anand Kapila K

(Last) (First) (Middle)
C/O ELANCO ANIMAL HEALTH INCORPORATED
2500 INNOVATION WAY

(Street)
GREENFIELD IN 46140

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Stock Units(1)(2) (3) 06/30/2025 A 603.9916 (1) (1) Common Stock 603.9916 $14.28(2)(3) 8,085.358 D
Explanation of Responses:
1. Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
2. The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
3. The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $14.28 on June 30, 2025.
/s/ Amy C. Seidel, as Attorney-in-Fact for Kapila K. Anand 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When will Eyenovia (EYEN) change its Nasdaq ticker to HYPD?

The company expects trading under the new ticker symbol HYPD to begin on July 3, 2025.

Does the name change to Hyperion DeFi, Inc. affect existing EYEN shareholders?

No. Shareholder voting rights, CUSIP number, and transferability of common stock remain unchanged.

What severance will departing COO Bren Kern receive?

Mr. Kern is entitled to 12 months of base salary and up to 12 months of health benefits continuation, subject to release conditions.

Was shareholder approval required for the corporate name change?

No. Under Delaware GCL §242, the board approved the amendment, and stockholder approval was not required.

Are there any financial results or guidance updates in this 8-K?

No financial metrics or updated guidance were disclosed; the filing is limited to governance and personnel matters.
Elanco Animal Health

NYSE:ELAN

ELAN Rankings

ELAN Latest News

ELAN Latest SEC Filings

ELAN Stock Data

6.83B
491.24M
0.88%
100.87%
2.92%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GREENFIELD